Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_assertion type Assertion NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_head.
- NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_assertion description "[Including this patient, we administered 150 mg erlotinib daily to nine NSCLC patients with CNS metastases and measured the plasma and CSF concentrations just before administration on day 8.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_provenance.
- NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_assertion evidence source_evidence_literature NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_provenance.
- NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_assertion SIO_000772 21681573 NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_provenance.
- NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_assertion wasDerivedFrom befree-2016 NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_provenance.
- NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_assertion wasGeneratedBy ECO_0000203 NP902788.RACYEe9vMmy_wnV6HFeDd_2K36uw8e9T0ocVK_5g4u66I130_provenance.